Polyphenol & Plant Antioxidants: Resveratrol, Quercetin & Green Tea EGCG Data

Overview #

Polyphenol actives — resveratrol, quercetin, and green tea EGCG — are among the most requested antioxidant ingredients we receive briefs on. The challenge isn’t sourcing them; it’s keeping them intact from the moment they hit the batch tank to the moment the consumer opens the bottle. Each of these three molecules degrades through different mechanisms, responds differently to pH and heat, and has its own list of incompatible co-ingredients. Brands developing antioxidant-forward serums and treatments need to understand these differences before locking in a formula — because what works beautifully at 100g lab scale can turn brown and lose 40% potency by week eight at production volume.

Degradation Mechanisms and Critical Stability Thresholds #

The first thing we establish in any polyphenol brief is which failure mode we’re designing against. These three actives don’t degrade the same way, and treating them as interchangeable is where most formulation problems start.

Resveratrol is a trans-isomer that undergoes photoisomerization to the biologically inactive cis form under UV exposure — even ambient lab lighting is enough to trigger measurable conversion over 48 hours. In our stability chamber, we’ve seen trans-resveratrol drop from 98% purity to below 70% after just 4 weeks at 40°C/75% RH in a clear glass vial. Opaque or UV-blocking packaging is non-negotiable. Beyond light, resveratrol is also sensitive to alkaline conditions: keep the formula above pH 7.0 and you’ll see accelerated oxidative browning within days. We target pH 4.5–5.5 for resveratrol-containing formulas, full stop.

Quercetin is the most oxidation-prone of the three. It carries a catechol group that reacts readily with dissolved oxygen, and in aqueous systems this is a real problem. We almost always push back on briefs that ask for quercetin in a water-based serum without an antioxidant support system. In our lab, unprotected quercetin in a simple hydrogel at pH 6.0 showed a 35% potency loss by week six under standard ICH accelerated conditions (40°C, 75% RH). The fix is chelation — disodium EDTA at 0.05–0.1% to bind trace metals that catalyze oxidation — combined with a nitrogen blanket during manufacturing. That combination typically extends stability to 12+ weeks under the same conditions. It’s not glamorous chemistry, but it works.

EGCG (epigallocatechin gallate) from green tea is arguably the most fragile of the three in aqueous formulas. It epimerizes and oxidizes simultaneously, and the rate accelerates sharply above pH 5.0. Below pH 4.0, epimerization slows significantly, but you’re now in territory that can irritate sensitive skin and — depending on your target market — may trigger regulatory scrutiny. We typically land EGCG formulas at pH 4.2–4.8, which is a narrow window. Temperature matters too: every 10°C increase roughly doubles the degradation rate. We don’t process EGCG-containing batches above 45°C, and we cool the batch before adding the active.

One thing brands consistently underestimate is the role of water activity. Even in anhydrous or low-water formats, residual moisture above 3% w/w can initiate hydrolytic degradation of EGCG’s gallate ester bond. We’ve had two projects where the formula looked stable in a standard emulsion but failed in a balm format — traced back to water migration from the humectant phase over time.

Incompatible Combinations and Co-Formulation Risks #

This is usually where projects go sideways. A brand will come to us with a “supercharged antioxidant” brief — resveratrol plus vitamin C plus niacinamide plus EGCG — and we have to walk them back through the compatibility matrix before we touch a beaker.

The most common conflict we see is resveratrol + L-ascorbic acid in the same aqueous phase. Both are unstable at high pH, which sounds like they’d be compatible — but L-ascorbic acid requires pH 2.5–3.5 for stability, while resveratrol performs best at pH 4.5–5.5. There’s no pH that makes both happy simultaneously. In practice, if a brand insists on both, we either encapsulate one of them (usually the resveratrol) or formulate them as a two-part system. Our encapsulation technology using cyclodextrin complexation can protect resveratrol at lower pH values, but it adds cost and lead time — something we flag upfront.

Quercetin + iron-containing actives is another combination we flag in every kickoff call. Quercetin chelates iron ions, which sounds beneficial until you realize it can also form colored complexes that turn the formula dark green or brown. We’ve seen this happen with certain botanical extracts that carry trace iron — the formula looks fine at day zero and is visibly discolored by week two. The solution is either removing the iron source or using a chelating agent to outcompete quercetin for the metal ions.

EGCG + proteins or peptides is a subtler issue. EGCG has a well-documented tendency to bind to proteins through hydrogen bonding and hydrophobic interactions. In a formula containing collagen peptides or growth factor proteins, EGCG can reduce the bioavailability of both actives. We’re still not fully convinced the clinical evidence on this interaction is strong enough to call it a definitive contraindication — but internally, we’ve observed reduced peptide activity in formulas where EGCG was present at concentrations above 0.5%. We now separate them into different delivery formats when both are requested.

Clinical Evidence and What It Actually Tells Us #

The head-to-head stability and efficacy data for these three actives is more useful than most brands realize — but you have to read it carefully. A 2020 randomized, double-blind, split-face clinical trial (n=44, 16 weeks) evaluating a stabilized resveratrol formulation at 1% concentration showed a 29% reduction in fine line depth and a 22% improvement in skin radiance scores versus vehicle control. What that study doesn’t tell you — and what we’ve learned from our own batches — is that the stabilization method matters as much as the concentration. The trial used a microencapsulated resveratrol with a lipid shell, not a straight aqueous dispersion. Brands who see “1% resveratrol” and assume any 1% formula will deliver the same result are setting themselves up for disappointment.

For EGCG, the SCCS Scientific Opinion on green tea extracts provides useful safety framing, but it doesn’t resolve the stability question. What we know from our own accelerated testing is that EGCG at 0.3–0.5% in a properly buffered, low-pH, nitrogen-processed formula retains above 90% potency at 12 weeks under ICH accelerated conditions. Above 0.5%, the stability curve gets less predictable — we’ve had batches hold and batches fail at the same nominal concentration, and we traced the variability back to raw material quality differences between suppliers.

Quercetin’s clinical data is honestly thinner than the ingredient’s popularity suggests. Most of the published efficacy data is in vitro or in food supplement contexts. We’re cautious about making strong on-pack claims for quercetin in topical applications without brand-specific clinical support. That said, its antioxidant synergy with vitamin E is well-characterized, and we routinely combine quercetin at 0.1–0.2% with tocopherol at 0.5% as a stabilizing antioxidant system rather than a primary active.

Regulatory compliance varies significantly by market. The EU Cosmetics Regulation 1223/2009 doesn’t specifically restrict any of these three polyphenols at typical cosmetic use levels, but the general safety assessment requirement means your stability data needs to be solid before you can substantiate claims. For the US market, FDA Cosmetics Guidelines apply the same principle — these are cosmetic ingredients, not drugs, so efficacy claims need to stay on the right side of the drug/cosmetic boundary. For brands targeting China, NMPA Cosmetic Regulation requires registration of new cosmetic ingredients, and EGCG from green tea extract is generally accepted under existing botanical ingredient frameworks, but the documentation burden is real.

Packaging Compatibility — The Variable Most Brands Get Wrong #

Honestly, most brands underestimate packaging as a stability variable. They’ll spend weeks optimizing the formula and then put it in whatever packaging their design team selected. We’ve seen resveratrol formulas that passed 12-week accelerated stability in our lab fail within 6 months in the brand’s chosen clear PET bottle — purely because of UV exposure through the packaging wall.

Our standard recommendation for all three polyphenols is airless pump dispensing in opaque or UV-blocking material. For resveratrol specifically, we require either an aluminum-laminate tube, an opaque HDPE airless, or amber glass with a UV-blocking overcap. Clear packaging is a hard no. For EGCG formulas, we also recommend nitrogen flushing of the headspace at fill — this adds a small cost at the filling line but meaningfully extends shelf life by reducing the oxygen available for oxidation.

One more thing: avoid metal-contact packaging components with quercetin formulas. We had a project where the brand specified a pump with a stainless steel spring — trace iron leaching from the spring was enough to initiate the discoloration reaction we described earlier. Switched to a plastic spring mechanism and the problem resolved. Small detail, significant consequence.

Formulation Notes for Brand Partners #

When you brief us on a polyphenol antioxidant formula, the first thing we need to know is your target market and your claims strategy. Those two inputs determine the pH window we’re working in, the stability standard we’re testing against, and whether we need to build in encapsulation from the start.

The most common brief mistake we see is requesting multiple polyphenol actives at “maximum efficacy” concentrations without a compatibility review. A brief that asks for 1% resveratrol, 0.5% EGCG, and 0.3% quercetin in a single aqueous serum is asking us to solve three separate stability problems simultaneously — and the solutions sometimes conflict. We’ll always push back on this and propose a tiered approach: lead with one primary active at a clinically relevant concentration, use the others as supporting antioxidants at lower levels where they contribute stability rather than compete for it.

We also need your packaging spec before we finalize the formula. Not after. Packaging affects the stability outcome, and we’ve learned the hard way that retrofitting a formula to a packaging change at week ten costs everyone time and money.

Timeline: lab samples in 2–3 weeks from brief sign-off, accelerated stability (40°C/75% RH, ICH protocol) running 4–8 weeks, with 24-month real-time stability initiated concurrently at the start of accelerated testing.

Frequently Asked Questions #

Q1: We want to put “1% resveratrol” on the pack — is that actually stable in a serum?
A: It depends entirely on the delivery format and packaging. Straight aqueous dispersion at 1% in a clear bottle? We’d give it maybe 6–8 weeks before meaningful potency loss. Microencapsulated in an opaque airless pump at pH 4.5–5.5? That’s a formula we can stand behind for 24 months.

Q2: Does the EU have any restrictions on EGCG concentration we need to know about?
A: No specific concentration cap under EU Cosmetics Regulation 1223/2009 for topical use at typical cosmetic levels, but your safety assessor will want stability data showing the active is intact at the claimed concentration through shelf life. Don’t assume the raw material spec sheet is enough.

Q3: We’ve heard quercetin can discolor formulas — how bad is this in practice?
A: Bad enough that we flag it in every kickoff call. The discoloration from quercetin-iron complexation can go from colorless to visibly brown or green within two weeks. We’ve seen it happen with botanical extracts that nobody suspected were carrying trace iron. Always run a compatibility screen before committing to a formula.

Q4: What’s your MOQ for a polyphenol antioxidant serum, and how long does development take?
A: MOQ is typically 500kg per batch for a finished serum. Full development — from brief to stability-confirmed formula ready for production — runs 3–5 months depending on complexity. If you’re combining multiple polyphenols with encapsulation, budget toward the longer end.

Q5: Should we be worried about combining these polyphenols with our existing vitamin C formula?
A: Yes, and this is the question most brands don’t think to ask until it’s too late. L-ascorbic acid needs pH 2.5–3.5 to stay stable; resveratrol and EGCG both degrade at that pH. Putting them in the same phase is a stability compromise for both actives. We almost always recommend a two-product system or encapsulation of one active — and we’d rather have that conversation at brief stage than after you’ve already committed to a formula.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.